444 related articles for article (PubMed ID: 29718793)
1. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data.
Lambertini M; Moore HCF; Leonard RCF; Loibl S; Munster P; Bruzzone M; Boni L; Unger JM; Anderson RA; Mehta K; Minton S; Poggio F; Albain KS; Adamson DJA; Gerber B; Cripps A; Bertelli G; Seiler S; Ceppi M; Partridge AH; Del Mastro L
J Clin Oncol; 2018 Jul; 36(19):1981-1990. PubMed ID: 29718793
[TBL] [Abstract][Full Text] [Related]
2. Gonadotropin-releasing hormone agonists for ovarian protection during cancer chemotherapy: systematic review and meta-analysis.
Senra JC; Roque M; Talim MCT; Reis FM; Tavares RLC
Ultrasound Obstet Gynecol; 2018 Jan; 51(1):77-86. PubMed ID: 29055060
[TBL] [Abstract][Full Text] [Related]
3. Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.
Munhoz RR; Pereira AA; Sasse AD; Hoff PM; Traina TA; Hudis CA; Marques RJ
JAMA Oncol; 2016 Jan; 2(1):65-73. PubMed ID: 26426573
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients.
Lambertini M; Boni L; Michelotti A; Magnolfi E; Cogoni AA; Mosconi AM; Giordano M; Garrone O; Arpino G; Poggio F; Cinacchi P; Bighin C; Fregatti P; Pronzato P; Blondeaux E; Del Mastro L;
J Natl Cancer Inst; 2022 Mar; 114(3):400-408. PubMed ID: 34850043
[TBL] [Abstract][Full Text] [Related]
5. Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain.
Turner NH; Partridge A; Sanna G; Di Leo A; Biganzoli L
Ann Oncol; 2013 Sep; 24(9):2224-35. PubMed ID: 23709175
[TBL] [Abstract][Full Text] [Related]
6. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials.
Del Mastro L; Ceppi M; Poggio F; Bighin C; Peccatori F; Demeestere I; Levaggi A; Giraudi S; Lambertini M; D'Alonzo A; Canavese G; Pronzato P; Bruzzi P
Cancer Treat Rev; 2014 Jun; 40(5):675-83. PubMed ID: 24360817
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and efficacy of gonadotropin-releasing hormone agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumours (KGOG 3048R).
Choi MC; Chung YS; Lee JW; Kwon BS; Park BK; Kim SI; Shim SH; Lee KB; Seong SJ; Lee SJ; Lee SH; Yoo HJ; Song T; Kim MK; Baek MH; Kang S; Kim YM
Eur J Cancer; 2020 Jul; 133():56-65. PubMed ID: 32442924
[TBL] [Abstract][Full Text] [Related]
8. Gonadotropin-releasing hormone agonists for ovarian protection during breast cancer chemotherapy: a systematic review and meta-analysis.
Li ZY; Dong YL; Cao XZ; Ren SS; Zhang Z
Menopause; 2022 Sep; 29(9):1093-1100. PubMed ID: 35917530
[TBL] [Abstract][Full Text] [Related]
9. Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a meta-analysis of randomized controlled trials.
Yang B; Shi W; Yang J; Liu H; Zhao H; Li X; Jiao S
Breast; 2013 Apr; 22(2):150-157. PubMed ID: 23298851
[TBL] [Abstract][Full Text] [Related]
10. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies.
Lambertini M; Ceppi M; Poggio F; Peccatori FA; Azim HA; Ugolini D; Pronzato P; Loibl S; Moore HC; Partridge AH; Bruzzi P; Del Mastro L
Ann Oncol; 2015 Dec; 26(12):2408-19. PubMed ID: 26347105
[TBL] [Abstract][Full Text] [Related]
11. The risk of menopausal symptoms in premenopausal breast cancer patients and current pharmacological prevention strategies.
Lei YY; Yeo W
Expert Opin Drug Saf; 2021 Oct; 20(10):1163-1175. PubMed ID: 33951990
[No Abstract] [Full Text] [Related]
12. Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival.
Zhang Y; Ji Y; Li J; Lei L; Wu S; Zuo W; Jia X; Wang Y; Mo M; Zhang N; Shen Z; Wu J; Shao Z; Liu G
Breast Cancer Res Treat; 2018 Apr; 168(3):679-686. PubMed ID: 29332135
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women.
Chen H; Xiao L; Li J; Cui L; Huang W
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD008018. PubMed ID: 30827035
[TBL] [Abstract][Full Text] [Related]
14. Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China: A Randomized Clinical Trial.
Zong X; Yu Y; Yang H; Chen W; Ding X; Liu S; Li X; Chen X; Jiang C; Xia X; Huang R; Zhu M; Hu J; Liang C
JAMA Oncol; 2022 Feb; 8(2):252-258. PubMed ID: 34967844
[TBL] [Abstract][Full Text] [Related]
15. Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy May Increase Pregnancy Rate in Survivors.
Blumenfeld Z; Zur H; Dann EJ
Oncologist; 2015 Nov; 20(11):1283-9. PubMed ID: 26463871
[TBL] [Abstract][Full Text] [Related]
16. New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients.
Del Mastro L; Rossi G; Lambertini M; Poggio F; Pronzato P
Cancer Treat Rev; 2016 Jan; 42():18-23. PubMed ID: 26613834
[TBL] [Abstract][Full Text] [Related]
17. No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial.
Demeestere I; Brice P; Peccatori FA; Kentos A; Dupuis J; Zachee P; Casasnovas O; Van Den Neste E; Dechene J; De Maertelaer V; Bron D; Englert Y
J Clin Oncol; 2016 Aug; 34(22):2568-74. PubMed ID: 27217453
[TBL] [Abstract][Full Text] [Related]
18. Gonadotropin-releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy: a systematic review and meta-analysis.
Vitek WS; Shayne M; Hoeger K; Han Y; Messing S; Fung C
Fertil Steril; 2014 Sep; 102(3):808-815.e1. PubMed ID: 25044080
[TBL] [Abstract][Full Text] [Related]
19. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Goel S; Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
[TBL] [Abstract][Full Text] [Related]
20. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
Bui KT; Willson ML; Goel S; Beith J; Goodwin A
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
